Related Experiment Video

Updated: May 23, 2026

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
09:32

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

Cardiovascular toxicity associated with small molecule tyrosine kinase inhibitors currently in clinical use

Constantin A Dasanu1, Premkumar Padmanabhan, Bernard A Clark

  • 1St. Francis Hospital and Medical Center, Department of Hematology-Oncology, Medical Oncology and Blood Disorders, LLP, Gothic Park, 43 Woodland Street, Suite G-80, Hartford, CT 06105, USA. c_dasanu@yahoo.com

Expert Opinion on Drug Safety
|April 4, 2012
PubMed
Abstract

Insights

Tyrosine kinase inhibitors (TKIs) offer advanced cancer treatment but can cause significant cardiovascular toxicity. Careful assessment of these risks is crucial for patient management.

Area of Science:

  • Oncology
  • Cardiology
  • Pharmacology

Background:

  • Tyrosine kinase inhibitors (TKIs) represent a significant advancement in treating advanced solid and hematologic malignancies.
  • Despite their efficacy, TKIs are associated with considerable cardiac and non-cardiac toxicities.

Purpose of the Study:

  • To comprehensively evaluate the adverse cardiovascular effects of small molecule TKIs.
  • To elucidate the underlying mechanisms of TKI-induced cardiovascular toxicities.
  • To provide recommendations for the prevention and management of these adverse events.

Main Methods:

  • Systematic review of the cardiovascular adverse event profile associated with small molecule TKIs.
  • Analysis of potential mechanisms driving kinase inhibitor-related cardiovascular toxicities.
  • Formulation of clinical recommendations for risk assessment and patient care.

Main Results:

  • Cardiovascular side effects of TKIs are diverse, including edema, heart failure, hypertension, and arrhythmias.
  • QTc prolongation can lead to serious events like acute coronary syndromes and cardiac arrest.
  • Clear links between specific kinase inhibition patterns and cardiovascular toxicity are often absent, suggesting multifactorial mechanisms.

Conclusions:

  • Cardiovascular toxicities from TKIs are likely due to the dysregulation of multiple kinase-regulated pathways.
  • Patients with pre-existing cardiac conditions require particular caution when initiating TKI therapy.
  • Balancing the oncologic benefits of TKIs against their cardiovascular risks is essential for optimal patient outcomes.

More Related Videos

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment04:48

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Published on: January 7, 2015

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However, frequent irregular...
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...